ClinicalTrials.gg
RecruitingNCT02744677Updated Jul 23, 2026

COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction

An interventional study of SAPIEN 3/SAPIEN 3 Ultra RESILIA THV and SAPIEN 3 THV in Complex Congenital Heart Defect, Dysfunctional RVOT Conduit and Pulmonary Valve Insufficiency, sponsored by Edwards Lifesciences. Recruiting at 27 sites in United States. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Edwards Lifesciences · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2016; still recruiting 10 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Pulmonary Valve Insufficiency with a site in United States — 2 open to participants now, 8 under way, none of them phase 3. Pulmonary Valve Insufficiency · United States.

Planned enrollment
2nd of 10
108 · median 75
Started
2016
the only one that year
No phase
10 of 15
2 open now
Registered
7th of 15
by date
Lead sponsor
7 of 15
Edwards Lifesciences

Among the 15 studies in Pulmonary Valve Insufficiency with a site in United States, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2016, is one of 10 with no phase, and was the 7th registered.

Pulmonary Valve Insufficiency

31 studies on the registry are indexed under Pulmonary Valve Insufficiency; 8 are open to participants now.

Browse Pulmonary Valve Insufficiency studies →

Open to participants now

2 of the 15 studies in Pulmonary Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Pulmonary Valve Insufficiency studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Pulmonary Valve Insufficiency with a site in United States, or all of them as a file.
02

Study summary

This study will demonstrate the safety and effectiveness of the Edwards Lifesciences SAPIEN 3/SAPIEN 3 Ultra RESILIA Transcatheter Heart Valve (THV) Systems in subjects with a dysfunctional right ventricular outflow tract (RVOT) conduit or previously implanted valve in the pulmonic position with a clinical indication for intervention.

03

Conditions studied

  • Complex Congenital Heart Defect
  • Dysfunctional RVOT Conduit
  • Pulmonary Valve Insufficiency
  • Pulmonary Valve Degeneration

Keywords

  • Tetralogy of Fallot
  • Aortic Valve Defect/Disease Resulting in Ross Procedure
  • Pulmonary Atresia
  • Pulmonary Stenosis
  • Truncus Arteriosus
  • Transposition of the Great Arteries
  • Transcatheter pulmonary valve implantation
  • Transcatheter pulmonary valve replacement
  • TPV
  • TPVR
  • TPVI
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Weight ≥ 20 kg (44 lbs.)
  2. Dysfunctional RVOT conduit or previously implanted valve in the pulmonic position with a clinical indication for intervention and with a landing zone diameter ≥ 16.5 mm and ≤ 29 mm immediately prior to study device insertion as per the Instructions for Use
  3. Subject presents with at least moderate PR and/or mean RVOT gradient ≥ 35 mmHg.
  4. The subject/subject's legally authorized representative has been informed of the nature of the study, agrees to its provisions and has provided written .

Exclusion criteria

Exclusion Criteria:

  1. Active infection requiring current antibiotic therapy (if temporary illness, subject may be a candidate 2 weeks after discontinuation of antibiotics)
  2. History of or active endocarditis (active treatment with antibiotics) within the past 180 days
  3. Leukopenia, anemia, thrombocytopenia or any known blood clotting disorder
  4. Inappropriate anatomy for femoral introduction and delivery of the study valve
  5. Need for concomitant atrial septal defect or ventricular septal defect closure or other concomitant interventional procedures other than pulmonary artery or branch pulmonary artery stenting or angioplasty
  6. Angiographic evidence of coronary artery compression that would result from transcatheter pulmonic valve implantation (TPVI)
  7. Interventional/surgical procedures within 30 days prior to the TPVI procedure.
  8. Any planned surgical, percutaneous coronary or peripheral procedure to be performed within the 30 day follow-up from the TPVI procedure.
  9. History of or current intravenous drug use
  10. Major or progressive non-cardiac disease resulting in a of less than one year
  11. Known to aspirin or heparin and cannot be treated with other antiplatelet and/or antithrombotic medications
  12. Known hypersensitivity to cobalt-chromium, nickel or contrast media that cannot be adequately premedicated
  13. Participating in another drug or device study that has not reached its primary endpoint.
  14. Female who is lactating or pregnant
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    TPVR - Main Cohort

    Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).

    Device: SAPIEN 3 THV

  • Experimental
    TPVR - THV Registry

    Subjects with a previously implanted transcatheter valve in the pulmonic position will undergo TPVR.

    Device: SAPIEN 3/SAPIEN 3 Ultra RESILIA THV

  • Experimental
    TPVR- S3UR Registry

    Subjects with a dysfunctional RVOT conduit or previously implanted surgical valve in the pulmonic position will undergo transcatheter pulmonary valve replacement (TPVR).

    Device: SAPIEN 3 Ultra RESILIA THV

Interventions

  • DeviceSAPIEN 3/SAPIEN 3 Ultra RESILIA THV

    SAPIEN 3/SAPIEN 3 Ultra RESILIA THV in the pulmonic position

  • DeviceSAPIEN 3 THV

    SAPIEN 3 THV in the pulmonic position

  • DeviceSAPIEN 3 Ultra RESILIA THV

    SAPIEN 3 Ultra RESILIA THV in the pulmonic position

06

What researchers measure

Primary outcomes

  1. THV dysfunction

    Defined as a non-hierarchical composite of: RVOT reintervention, Moderate or greater total pulmonary regurgitation (PR) via Transthoracic Echocardiography (TTE), Mean RVOT gradient \> 40 mmHg via TTE

    Time frame: 1 year

Secondary outcomes

  1. Device Success

    Defined as a composite of: 1) Single THV implanted in the desired location, 2) RV-PA peak-to-peak gradient \< 35 mmHg post-implantation, 3) Less than moderate PR by discharge TTE (or earliest evaluable TTE), 4) Free of explant at 24 hours post-implantation.

    Time frame: Discharge, expected to be within 1-5 days post-procedure

  2. Mean RVOT gradient

    Time frame: 6 months

  3. Paravalvular and total PR

    Time frame: 6 months

  4. RVOT reintervention

    Time frame: 6 months

  5. Coronary artery compression requiring intervention

    Time frame: 30 days

  6. Major vascular complications

    Time frame: 30 days

  7. Life-threatening or disabling bleeding

    Time frame: 30 days

  8. THV frame fracture

    Time frame: 6 months

  9. Device-related endocarditis

    Time frame: 1 year

  10. Death (all-cause, procedural and device-related)

    Time frame: 1 year

07

Study locations

21 of 27 sites recruiting
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
    Recruiting
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
    Recruiting
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
    Completed

    Not enrolling at this site — choose another above.

  • University of California,, San Francisco (UCSF)
    San Francisco, California 94143, United States
    Recruiting
  • Childrens Hospital of Colorado
    Aurora, Colorado 80045, United States
    Recruiting
  • Emory University/Children's Healthcare of Atlanta
    Atlanta, Georgia 30322, United States
    Recruiting
  • University of Kentucky
    Lexington, Kentucky 40536, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Recruiting
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
    Recruiting
  • St. Louis Children's Hospital
    St Louis, Missouri 63110, United States
    Recruiting
  • Washington University Barnes- Jewish Medical/ St. Louis Children's Hospital
    St Louis, Missouri 63110, United States
    Completed

    Not enrolling at this site — choose another above.

  • Columbia University Medical Center/NYPH
    New York, New York 10032, United States
    Recruiting
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
    Recruiting
  • The Lindner Research Center at Christ Hospital
    Cincinnati, Ohio 45219, United States
    Completed

    Not enrolling at this site — choose another above.

  • Cincinnati Children's Hospital
    Cincinnati, Ohio 45229, United States
    Recruiting
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
    Recruiting
  • Penn Presbyterian Medical Center, University of Pennsylvania/ Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
    Completed

    Not enrolling at this site — choose another above.

  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
    Recruiting
  • LeBonheur Children's Hopsital
    Memphis, Tennessee 38103, United States
    Recruiting
  • Vanderbilt University
    Nashville, Tennessee 37232, United States
    Recruiting
  • Medical City Dallas
    Dallas, Texas 75230, United States
    Recruiting
  • Children's Health System of Texas / UT Southwestern Medical Center
    Dallas, Texas 75235, United States
    Recruiting
  • Methodist San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
  • Intermountain Heart Institute (IMC)
    Murray, Utah 84107, United States
    Recruiting
  • University of Virginia (UVA)
    Charlottesville, Virginia 22908, United States
    Recruiting
  • University of Washington/Seattle Children's Hospital
    Seattle, Washington 98195, United States
    Completed

    Not enrolling at this site — choose another above.

08

References and documents

Publications

  • Lim DS, Kim D, Aboulhosn J, Levi D, Fleming G, Hainstock M, Sommer R, Torres AJ, Zhao Y, Shirali G, Babaliaros V. Congenital Pulmonic Valve Dysfunction Treated With SAPIEN 3 Transcatheter Heart Valve (from the COMPASSION S3 Trial). Am J Cardiol. 2023 Mar 1;190:102-109. doi: 10.1016/j.amjcard.2022.12.010. Epub 2023 Jan 4. PubMed 36608435 ↗
  • Hainstock MR, Fleming G, Kim D, Aboulhosn J, Levi D, Krasuski R, Sommer R, Torres AJ, Gray R, Kereiakes D, Leventhal A, Gillespie M, Szeto W, Zajarias A, Shahanavaz S, Steinberg ZL, Jones TK, Mahadevan VS, Moore P, Elmariah S, Shirali G, Li W, Babaliaros V, Lim DS; COMPASSION 3 Trial Executive Committee and Study Investigators. Five-Year Outcomes for Patients With RVOT Dysfunction Treated With the SAPIEN 3 Transcatheter Heart Valve: A Pooled Analysis From the COMPASSION S3 Trial. Circ Cardiovasc Interv. 2026 May;19(5):e016361. doi: 10.1161/CIRCINTERVENTIONS.125.016361. Epub 2026 Mar 26. PubMed 41884901 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2016 (actual). Primary completion is estimated for Dec 2026, 125 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2016
First posted
Apr 20, 2016
StartActual
Jul 5, 2016
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2031
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02744677
Responsible party
Sponsor
First posted
Apr 20, 2016
Start date
Jul 5, 2016
Primary completion
Dec 2026 (estimated)
Completion
Jun 2031 (estimated)
Last update
Jul 23, 2026

Study contacts

Edwards THV Clinical Affairs
Contact
THV_CT.gov@Edwards.com
(949) 250-2500
D. Scott Lim, MD
principal investigator · University of British Columbia
Vasilis Babaliaros, MD
principal investigator · Emory University Hospitals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion